Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Azilsartan medoxomil
Drug ID BADD_D00202
Description Azilsartan medoxomil is a prodrug that is broken down to azilsartan, which belongs in the angiotensin-receptor blocking (ARB) drug class. It is a selective AT1 subtype angiotensin II receptor antagonist. Azilsartan medoxomil is a relatively recently-developed antihypertensive drug that was first approved by the FDA in February 2011.[A7354] Many guidelines recommend the use of ARBs as first-line therapy when initiating antihypertensive therapy and indicate that the clinical efficacy of ARBs is comparable to angiotensin-converting enzyme (ACE) inhibitors that are also used as first-line treatment for hypertension.[A232863] Azilsartan medoxomil is marketed under the brand name Edarbi. It is used to treat hypertension as monotherapy or in combination with other antihypertensive drugs. It is also available in a combination product with [chlorthalidone]. As hypertension is a major risk factor for cardiovascular disease,[A7354] early management of hypertension has several implications on patients' survival rate and quality of life in the future. Lowering blood pressure is associated with a reduced risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.[L32918] Azilsartan medoxomil is thus speculated to lower mortality rates and the onset of cardiovascular disease. Although there is no clinical significance yet determined, azilsartan medoxomil may have potential off-label uses in patients with a history of myocardial infarction or heart failure.[A232863]
Indications and Usage Treatment of hypertension (alone or as an adjunct).
Marketing Status Not Available
ATC Code C09CA09
DrugBank ID DB08822
KEGG ID D08067
MeSH ID C557413
PubChem ID 135409642
TTD Drug ID D0A2RA
NDC Product Code 66332-2003; 66332-2002
Synonyms azilsartan medoxomil | TAK 491 | TAK491 | TAK-491
Chemical Information
Molecular Formula C30H24N4O8
CAS Registry Number 863031-21-4
SMILES CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NOC(=O)N5)C(=O)OCC6=C(OC(=O)O6) C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.0070.000153%
Platelet count abnormal13.01.04.005--Not Available
Pruritus23.03.12.001--
Pulmonary embolism24.01.06.001; 22.06.02.0010.000153%Not Available
Rash23.03.13.001--Not Available
Rash generalised23.03.13.0020.000153%Not Available
Red blood cell count decreased13.01.05.007--Not Available
Renal failure20.01.03.0050.000040%Not Available
Skin disorder23.03.03.007--Not Available
White blood cell count abnormal13.01.06.028--Not Available
Angiopathy24.03.02.007--Not Available
Connective tissue disorder15.06.01.006--Not Available
Drug intolerance08.06.01.0130.000153%Not Available
The 2th Page    First    Pre   2    Total 2 Pages